Close-up of sample being place into microplate

Research Lab Overview

The long-term goal of Dr. Chen’s research program is to provide novel opportunities for advanced leukemia/cancer therapies by understanding how genetic/epigenetic regulators and their networks control gene expression, epigenetic landscape, and genome integrity under normal and disease conditions. His prior study based on a genome-wide functional genomic screen has identified cross-inhibitory genetic interactions between multiple chromatin effectors in MLL-r leukemias, a highly malignant disease that affects about 50% of infant acute leukemia patients (and nearly 10% of the acute leukemia in all patients). These results have been published in Nature Medicine (Chen et al. 2015) and have led his current research towards combinational therapies for multiple types of malignant diseases. His recent publications include Mol Cell (2015, 2017, 2021), Nat Med (2015, 2016), Cell (2018), Blood (2019, 2019, 2020, 2021, 2022, 2022), Genes & Development (2019), Sci Transl Med (2019, 2023), Front Cell Dev Biol (2019*), J Clin Invest (2016, 2022), Cell Stem Cell (2020, 2023), Cells (2020*, 2023), Nature (2020, 2020), Cancer Discovery (2016, 2020, 2022, 2023), Leukemia (2022*), Adv Sci (2023*), Nat Cell Biol (2022), Sci Adv (2022*) and Nat Commun (2021*, 2022, 2023). Dr. Chen also leads technological development and pioneered a single-cell CRISPR gene tiling pipeline “sc-Tiling” for structural/functional genomics and therapeutic pocket discovery (Yang et al. 2021, Nat Commun*)(*corresponding).

Dr. Chen’s research program is funded by several NIH (R37 MERIT, R01s, K99/R00) and foundation (ASH Scholar, ALSF Innovation) awards. He also supports consortium research efforts including a NIH/NCI U54 FusOnC2 (PI: Charles Mullighan) and a SU2C-CRUK Pediatric Cancer New Discoveries Challenge (PI: Alex Bishop).

Dr. Chen has more than 10 years research experience in high-throughput genetic screens (CRISPR, RNAi), fusion oncoproteins (MLL-r, NUP98-fusions, EWS-FLI1), pediatric cancers (leukemia, Ewing sarcoma), and epigenetic mechanisms.

Principal Investigator: Chun-Wei (David) Chen, Ph.D.

As an Associate Professor of Department of Systems Biology and Department of Neurodegenerative Diseases, and as a member of City of Hope Comprehensive Cancer Center, David Chen also serves as Director of Division of Epigenetics and Transcriptional Engineering at City of Hope. His lab focuses on epigenetic mechanisms, drug resistance, and therapeutic target discovery in cancers using high throughput genetic screens.

Full bio

Lab Members

Anthony Chan, Ph.D.

Staff Scientist

Research Focus Molecular cell biology and epigenetics in cancer research Therapeutic target discovery using high-throughput CRISPR genetic screens Drug discovery using a combination of in silico modeling, in vitro binding assays, and cell-based methods Full Bio

Shai Izraeli, M.D.

Research Professor

Research Focus Hematologic malignancies Cancer predisposition syndromes Centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer Full bio

Mingli Li, Ph.D.

Staff Scientist

Research Focus Molecular cell biology and biochemistry in cancer research Drug discovery using cell-based disease model screening Identification of novel therapeutic targets to eliminate cancer cells Full bio

Priyanka Singh

Postdoctoral Fellow

Dr. Priyanka Singh obtained her Ph.D. from the Post Graduate Institute of Medical Education and Research, India. She is experienced in epigenetics and molecular biology techniques which help find new treatments for cancer patients. Dr. Singh joined David Chen’s laboratory at the Department of Systems Biology in March 2022. Her current projects focus on identifying novel therapeutic targets in leukemia using genetic and epigenetic approaches using CRISPR-based systems.Research Focus Investigation and identification of genes related to epigenetics in leukemia using CRISPR library screening Degrees 2015-2020, Ph.D., Post Graduate Institute of Medical Education and Research, Chandigarh, India 2010-2012, M.Sc. (Hons), Biochemistry, Panjab University, Chandigarh, India 2007-2010, B.Sc. (Hons), Biochemistry, Panjab University, Chandigarh, India Fellowships 2022-present, Fellowship, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA 2015-2020, Junior and Senior Research Fellowship, Indian Council of Medical Research, India 2014, National Eligibility Test-Lectureship, Council of Science and Industrial Research, India Professional Experience 2022-present, Postdoctoral Fellow, Beckman Research Institute of City of Hope, Monrovia, CA 2021-2022, Research Associate, National Institute of Malaria Research-ICMR, New Delhi, India 2015-2020, Ph.D. Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Awards 2020, Second Prize in Oral Presentation in Indian Society for Bone and Mineral Research, India 2020, Travel Award (ECTS-East meets West award) European Calcified Tissue Society, France (virtual event) 2020, Young Investigator Emerging Country Award, American Society of Bone and Mineral Research (virtual event) 2019, First prize in oral presentation in Indian Society for Bone and Mineral Research, Bangalore, India 2018, YUVA scholarship, NextGen Genomics, Biology, Bioinformatics and Technologies Conference, Jaipur, India 2018, Women in Endocrinology “Young Investigator Award," ENDO US, Chicago, IL 2016, Young Investigator Award, International Osteoporosis Foundation Meeting, Singapore Memberships Member of Indian Society of Bone and Mineral Research (ISBMR), India Publications Singh, P., Bhadada, S.K., Dahiya, D., Arya, A.K., Saikia, U.N., Kaur, J., Sachdeva, N., Behera, A., Brandi, M.L., & Rao, S.D. GCM2 Silencing in Parathyroid Adenoma is associated with Promoter Hypermethylation and Gain of Methylation on Histone 3, Journal of Clinical Endocrinology and Metabolism. 2021Singh, P., Bhadada, S.K., Arya, A.K., Saikia, U.N., Dahiya, D., Kaur, J., Sachdeva, N., Brandi, M.L., & Rao, S.D. Aberrant epigenetic alteration of PAX1 expression contributes to parathyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism. 2021Singh, P., Bhadada, S.K., Dahiya, D., Arya, A.K., Saikia, U.N., Kaur, J., Sachdeva, N., Brandi, M.L., & Rao, S.D., Reduced Calcium Sensing Receptor is Epigenetically Inactivated in Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism. 2020Arya, A.K., Kumari, P., Bhadada, S.K., Agrawal, K., Singh, P., Mukherjee, S., Sood, A., & Rao, S.D. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab. 2020Pal, R., Arya, A.K., Aggarwal, A., Singh, P., Dahiya, D., Sood, A., Singh, T., Ram, S., Bhansali, A., & Bhadada, S.K. Weight gain after curative parathyroidectomy predicts increase in bone mineral density in patients with symptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf). 2020Singh, P., Vadi, S.K., Saikia, U.N., Sood, A., Dahiya, D., Arya, A.K., Behera, A., Mukherjee, S., Arvindkumar, S.M., & Bhadada, S.K. Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features. Clinical Endocrinology (Oxf). 2019Arya, A.K., Bhadada, S.K., Singh, P., Sachdeva, N., Saikia, U.N., Dahiya, D., Behera, A., Bhansali, A., & Rao, S.D., Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas. Sci Rep. 2017

Priyanka Singh

Postdoctoral Fellow

Research Focus

Investigation and identification of genes related to epigenetics in leukemia using CRISPR library screening

Degrees

2015-2020, Ph.D., Post Graduate Institute of Medical Education and Research, Chandigarh, India
2010-2012, M.Sc. (Hons), Biochemistry, Panjab University, Chandigarh, India
2007-2010, B.Sc. (Hons), Biochemistry, Panjab University, Chandigarh, India

Fellowships

2022-present, Fellowship, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA
2015-2020, Junior and Senior Research Fellowship, Indian Council of Medical Research, India
2014, National Eligibility Test-Lectureship, Council of Science and Industrial Research, India

Professional Experience

2022-present, Postdoctoral Fellow, Beckman Research Institute of City of Hope, Monrovia, CA
2021-2022, Research Associate, National Institute of Malaria Research-ICMR, New Delhi, India
2015-2020, Ph.D. Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Awards

2020, Second Prize in Oral Presentation in Indian Society for Bone and Mineral Research, India
2020, Travel Award (ECTS-East meets West award) European Calcified Tissue Society, France (virtual event)
2020, Young Investigator Emerging Country Award, American Society of Bone and Mineral Research (virtual event)
2019, First prize in oral presentation in Indian Society for Bone and Mineral Research, Bangalore, India
2018, YUVA scholarship, NextGen Genomics, Biology, Bioinformatics and Technologies Conference, Jaipur, India
2018, Women in Endocrinology “Young Investigator Award," ENDO US, Chicago, IL
2016, Young Investigator Award, International Osteoporosis Foundation Meeting, Singapore

Memberships

Member of Indian Society of Bone and Mineral Research (ISBMR), India

Publications

Singh, P., Bhadada, S.K., Dahiya, D., Arya, A.K., Saikia, U.N., Kaur, J., Sachdeva, N., Behera, A., Brandi, M.L., & Rao, S.D. GCM2 Silencing in Parathyroid Adenoma is associated with Promoter Hypermethylation and Gain of Methylation on Histone 3, Journal of Clinical Endocrinology and Metabolism. 2021
Singh, P., Bhadada, S.K., Arya, A.K., Saikia, U.N., Dahiya, D., Kaur, J., Sachdeva, N., Brandi, M.L., & Rao, S.D. Aberrant epigenetic alteration of PAX1 expression contributes to parathyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism. 2021
Singh, P., Bhadada, S.K., Dahiya, D., Arya, A.K., Saikia, U.N., Kaur, J., Sachdeva, N., Brandi, M.L., & Rao, S.D., Reduced Calcium Sensing Receptor is Epigenetically Inactivated in Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism. 2020
Arya, A.K., Kumari, P., Bhadada, S.K., Agrawal, K., Singh, P., Mukherjee, S., Sood, A., & Rao, S.D. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab. 2020
Pal, R., Arya, A.K., Aggarwal, A., Singh, P., Dahiya, D., Sood, A., Singh, T., Ram, S., Bhansali, A., & Bhadada, S.K. Weight gain after curative parathyroidectomy predicts increase in bone mineral density in patients with symptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf). 2020
Singh, P., Vadi, S.K., Saikia, U.N., Sood, A., Dahiya, D., Arya, A.K., Behera, A., Mukherjee, S., Arvindkumar, S.M., & Bhadada, S.K. Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features. Clinical Endocrinology (Oxf). 2019
Arya, A.K., Bhadada, S.K., Singh, P., Sachdeva, N., Saikia, U.N., Dahiya, D., Behera, A., Bhansali, A., & Rao, S.D., Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas. Sci Rep. 2017

Leisi Zhang

Visiting Scholar

Research Focus Mechanisms underlying the therapeutic resistance in leukemia Education 2009-2017, M.D., Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China Professional Experience 2021-present, Visiting Scholar, Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 2017-present, Internist, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Publications Zhang, L., Wang, J., Xu, M., Wu, T., Huang, S., Cao, H., Sun, A., Liu, S., & Xue, S. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine. OncoTargets and therapy 2022, 15:159-164.Kong, J., Hao, Y., Wan, S., Li, Z., Zou, D., Zhang, L., Lu, Y., Wang, J., Chen, X., & Fu, J. Comparative study of hematological and radiological feature of severe/critically ill patients with COVID-19, influenza A H7N9, and H1N1 pneumonia, J Clin Lab Anal 2021 35(12):e24100.Yang, Q., Chen, K., Zhang, L., Feng, L., Fu, G., Jiang, S., Bi, S., Lin, C., Zhou, Y., Zhao, H., Chen, X., Fu, G. & Xu, B. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. CANCER LETT 2019, 461: 31-43.Zhang, L., Zhou, Y., Chen, K., Shi, P., Li, Y., Deng, M., Jiang, Z., Wang, X., Li, P. & Xu, B. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. TARGET ONCOL 2017, 12(5): 677-687. Li, Y., Wang, Y., Zhou, Y., Li, J., Chen, K., Zhang, L., Deng, M., Deng, S., Li, P. & Xu, B. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells, Clinical Epigenetics, 2017.8, 9(83).Shi, P., Zhang, L., Chen, K., Jiang, Z., Deng, M., Zha, J., Guo, X., Li, P., & Xu, B. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage, Pharmacogenomics, 2017.8, 18(13): 1259~1270.

Leisi Zhang

Visiting Scholar

Research Focus

Mechanisms underlying the therapeutic resistance in leukemia

Education

2009-2017, M.D., Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China

Professional Experience

2021-present, Visiting Scholar, Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA
2017-present, Internist, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Publications

Zhang, L., Wang, J., Xu, M., Wu, T., Huang, S., Cao, H., Sun, A., Liu, S., & Xue, S. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine. OncoTargets and therapy 2022, 15:159-164.
Kong, J., Hao, Y., Wan, S., Li, Z., Zou, D., Zhang, L., Lu, Y., Wang, J., Chen, X., & Fu, J. Comparative study of hematological and radiological feature of severe/critically ill patients with COVID-19, influenza A H7N9, and H1N1 pneumonia, J Clin Lab Anal 2021 35(12):e24100.
Yang, Q., Chen, K., Zhang, L., Feng, L., Fu, G., Jiang, S., Bi, S., Lin, C., Zhou, Y., Zhao, H., Chen, X., Fu, G. & Xu, B. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. CANCER LETT 2019, 461: 31-43.
Zhang, L., Zhou, Y., Chen, K., Shi, P., Li, Y., Deng, M., Jiang, Z., Wang, X., Li, P. & Xu, B. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. TARGET ONCOL 2017, 12(5): 677-687.
Li, Y., Wang, Y., Zhou, Y., Li, J., Chen, K., Zhang, L., Deng, M., Deng, S., Li, P. & Xu, B. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells, Clinical Epigenetics, 2017.8, 9(83).
Shi, P., Zhang, L., Chen, K., Jiang, Z., Deng, M., Zha, J., Guo, X., Li, P., & Xu, B. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage, Pharmacogenomics, 2017.8, 18(13): 1259~1270.

Join Our Team

Join one of our labs and help us on our mission to save lives.

Our Publications

CRISPR-tiling instructed structural genetic screen identifies a novel class inhibitor that disrupts the integrin heterodimer stability.

Mattson N, Chan ANK, Miyashita K, Mukhaleva E, Chang WH, Yang L, Ma N, Wang Y, Pokharel SP, Li M, Liu Q, Xu X, Chen R, Singh P, Zhang L, Elsayed Z, Chen B, Keen D, Pirrotte P, Rosen ST, Chen J, LaBarge MA, Shively JE, Vaidehi N, Rockne RC, Feng M, and Chen CW. Nature Structural Molecular Biology (accepted 2023-10-11; IF=18.3).

TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.

Wu, G., Yoshida, N., Liu, J., Zhang, X., Xiong, Y., Heavican-Foral, T. B., Mandato, E., Liu, H., Nelson, G. M., Yang, L., Chen, R., Donovan, K. A., Jones, M. K., Roshal, M., Zhang, Y., Xu, R., Nirmal, A. J., Jain, S., Leahy, C., Jones, K. L., … Brown, M. (2023). Science translational medicine, 15(714), eadi7244.

Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.

Card Link URL

https://doi.org/10.1002/advs.202206584

Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, Xu X, Chang WH, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, Chan LN, Lee J, Zhang XH, Rosen ST, Müschen M, Qi J, Chen J, Hiom K, Bishop AJR, Chen CW. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(17), e2206584.

Research Highlights

High-throughput genetic screen pipeline:

Single-cell CRISPR tiling scan:

CRISPR multiomics:

Lab News

2023

March 2023, Welcome! Zeinab Elsayed (postdoc)
April 2023, Nicole Mattson (PhD student) received AACR Scholar-in-Training Award
June 2023, Mingli Li (postdoc) published in Advanced Sciences June 2023, Welcome! Li-Hui Lien (COH/NTU Summer Program)
June 2023, Welcome! Yu-Hsin Cheng (COH/NTU Summer Program)
June 2023, Welcome! Pradeep Bompada (postdoc)
August 2023, Welcome! Benjamin Kuang (PhD student)
September 2023, David Chen received NCI CBC NExT Award
September 2023, Mingli Li (postdoc) published in Cells
September 2023, Nicole Mattson (PhD student) passed thesis defense!
October 2023, Nicole Mattson (PhD student) paper accepted at Nature Structural Molecular Biology
December 2023, Leisi Zhang’s project oral presented at ASH annual meeting

2022

January 2022, Qiao Liu (Ph.D. student) published in Leukemia
March 2022, Welcome! Priyanka Singh (postdoc)
April 2022, Mingli Li (postdoc) received AACR Scholar-in-Training Award
April 2022, Nicole Mattson (Ph.D. student) received AACR Scholar-in-Training Award
April 2022, Xiaobao Xu (postdoc) presented at AACR
April 2022, Welcome! Leisi Zhang (postdoc)
April 2022, David Chen presented at The Science of Childhood Cancer Series, St. Jude
May 2022, David Chen was appointed Associate Professor, Pediatrics (secondary appointment)
June 2022, Mingli Li (postdoc) received the Sarcoma Foundation of America Award
June 2022, Mingli Li (postdoc) published in Biomedicines
June 2022, Welcome! Grace Aranda (CIRM Summer Fellow)
July 2022, Welcome! David Gomez-Novy (CRISPR Summer Program)
August 2022, Nicole Mattson (Ph.D. student) received NIH/NCI F99 Award
September 2022, David Chen received 2022 Professor of the Year – City of Hope
October 2022, Mingli Li (postdoc) published in Cancers
December 2022, David Chen received NIH/NCI R01 CA278050 Award
December 2022, Xiaobao Xu (postdoc) published in Science Advances

2021

January 2021, Alex Bishop (UTHSCSA) received SU2C-CRUK Award (Chen: co-I)
January 2021, Srividya Swaminathan (COH) received LLS Research Award (Chen: co-I)
May 2021, Michelle Garcia (Pomona College) received Goldwater Scholar
June 2021, David Chen presented at 10X Genomics CRISPR Functional Genomics Symposium
June 2021, Welcome! Renee Chen (CRISPR Summer Program)
June 2021, Welcome! Maggie Li (Roberts Summer Program)
July 2021, Lu Yang (Research Assistant Prof.) published in Nature Communications
July 2021, David Chen appointed NCI-I Study Section member
September 2021, David Chen presented at Genome Engineering Seminar, Harvard Medical School
October 2021, Nicole Mattson (PhD student) received Payson Scholarship
November 2021, David Chen appointed Associate Professor, Systems Biology

2020

January 2020, Kazuya Miyashita (postdoc) received Uehara Scholarship
March 2022, COVID lockdown till June 2022
March 2020, David Chen was appointed IBC member
May 2020, David Chen presented at Dana-Farber/Harvard Cancer Center (DF/HCC) Connect
May 2020, Michelle Garcia (Pomona College) received Caltech/Genentech WAVE Fellow
August 2020, Qiao Liu (Ph.D. student) published in Cells
August 2020, David Chen received NIH/NCI ITCR Award

2019

January 2019, Welcome! Xiaobao Xu (postdoc)
February 2019, Welcome! Qiao Liu (Ph.D. student)
April 2019, David Chen received NIH/NCI R01 Award
May 2019, Welcome! Nicole Mattson (Ph.D. student)
May 2019, Anthony Chan (postdoc) published in Frontiers in Cell and Developmental Biology
June 2019, Welcome! Michelle Garcia (COH/Pomona College Intern Program)
July 2019, Welcome! Po-Wei Chiu (NTU/COH Summer Program)
August 2019, Welcome! Yi-Wei Chiang (MOST Scholarship)
September 2019, Charles Mullighan (St. Jude) received U54 Award (David Chen leads Genome Editing Core)
October 2019, David Chen received ALSF Innovation Award
October 2019, David Chen received COSF Research Award
October 2019, Welcome! Wei Lu (computational postdoc)
December 2019, David Chen presented at TRTH, ASH
December 2019, Anthony Chan (postdoc) presented at ASH annual meeting (Travel Award)

2018

April 2018, Welcome, Kazuya Miyashita (postdoc)
June 2018, Welcome, Sandra Li (Roberts Summer Program)
July 2018, David Chen received ASH Scholar Award
July 2018, Steven Rosen (COH) received LLS Research Award (Chen: co-I)
September 2018, David Chen presented at Illumina Sequencing Innovation Symposium
December 2018, Steven Rosen (COH) received NIH/NCI R01 Award (Chen: co-I)
December 2018, David Chen presented at ASH annual meeting
December 2018, Welcome, Mingli Li (postdoc)
December 2018, David Chen received NIH/NCI R37 MERIT Award

2017

July 2017, Grand Opening — David Chen Lab at City of Hope
July 2017, David Chen appointed Assistant Professor, Systems Biology
July 2017, David Chen appointed Director of Epigenetic and Transcriptional Engineering
October 2017, Welcome! Anthony Chan (postdoc)
November 2017, Welcome! Sheela Pangeni Pokharel (Lab Manager)
December 2017, Welcome! Lu Yang (Research Assistant Professor, Bioinformatician)
December 2017, Welcome! Wen-Han Chang (postdoc)

2016